July 31, 2020 -- Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit enhanced neutralization upon combinatorial testing.
Previously, the company demonstrated potent in vitro neutralizing activity of functional antibodies discovered using its DeepDisplay phage technology, B Cell Select, and single-step hybridoma platforms. Now, the company has confirmed that six antibodies covering three epitopes analyzed for enhanced function in combination studies resulted in near complete SARS-CoV-2 pseudovirus infection.
Efforts continue to further analyze multiple additional subsets of antibodies including neutralizing antibodies that bind to the S1 and S2 subunit domains of the SARS-CoV-2 spike protein. The company has begun steps for expression of the lead antibodies for preclinical and clinical manufacturing.